Specify a stock or a cryptocurrency in the search bar to get a summary
OptiNose
OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. Address: 1020 Stony Hill Road, Yardley, PA, United States, 19067
Analytics
WallStreet Target Price
3.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OPTN
Dividend Analytics OPTN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OPTN
Stock Valuation OPTN
Financials OPTN
Results | 2019 | Dynamics |